et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282–1295 (2015). Article CAS PubMed PubMed Central Google Scholar Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune ...
(Table 1) Universal "off the shelf" CART A total of 68 patients from 8 studies were evaluated. Median age was 22.5 (4.8-64) years and 64% were males (n= 9/14). The median follow-up time was 10 (2-18) months. Underlying diagnosis was ALL 72% (n= 49), chronic lymphocytic ...
About ScienceDirect Remote access Shopping cart Advertise Contact and support Terms and conditions Privacy policy Cookies are used by this site. Cookie Settings All content on this site: Copyright © 2025 or its licensors and contributors. All rights are reserved, including those for text and ...
(Fig.1c). The UCART123 activity against leukemia cells was comparable to CART123 cells. Supplementary Table2, shows the specific characteristics of the UCART123 cells used for the study. It is important to note the high efficiency of the inactivation of TRAC ( < 1% TCR αβ+; ...
Abstract LB-053: Next-generation sequencing of T-cell receptor-beta gene rearrangements reveals dramatic expansion of T-cell clonotypes after CART-EGFRvIII therapy for glioblastoma react-text: 78 In allogeneic hematopoietic stem cell transplantation (HSCT), controlling graft-versus-host disease (GVHD) ...
The potential of induced pluripotent stem cells as a tool to study skeletal dysplasias and cartilage-related pathologic .诱导多能干细胞的潜力作为一种工具来研究骨骼发育不良和cart 热度: nucleosome assembly protein 1-like 1(nap1l1)regulates the proliferation of murine induced pluripotent stem cells....
Philadelphia positive acute lymphoblastic leukemia (Ph + ALL) is the largest genetically defined subtype in adult ALL, affecting about 25% of adults with ALL, particularly those older than 40 years...
Despite the approval of three autologous CAR-T cell products, B-cell malignancies still represent an unmet need as several of the relapsed/refractory patients are ineligible for autologous CART cell therapies. Invariant natural killer T (iNKT) cells are a unique subset of immune cells that display...
Combination antiretroviral therapy (cART) has enabled the treatment of medical conditions in patients infected with the human immunodeficiency virus (HIV) in the same way as in the general population. Moreover, improvements in supportive care have allowed HIV-infected patients with life-threatening ...
Individuals who were in CR (negative for measurable residual disease) after CD19-CART administration could proceed to allo-HSCT at the discretion of the treating physician, presumably based on their medical fitness and donor availability, with the intensity of the conditioning regimen also determined ...